Linq Therapeutics Private Limited, a active private limited company, was established on 29 September 2015 in Pune City, Maharashtra, India. Engaging in diagnostic centers & pathology labs within the healthcare sector, it holds CIN: U74999PN2015PTC156595. Registered under ROC Roc Pune. it is unlisted. It has an authorized capital of ₹5.00 M and a paid-up capital of ₹5.00 M.
It upholds a compliant status. Employing 5 professional, Its leadership includes Pathik Pradeep Divate (Director), Uma Pradeep Divate (Director), Cowasji Jehangir Jehangir (Director). Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Office No. 309-311, Millenium Star,, P 17 Fp 153 Cts 36 To 40, Sangamwadi, Pune City, Maharashtra, 411001.
U74999PN2015PTC156595
156595
29 September 2015
₹5.00 M
₹5.00 M
Roc Pune
Unlisted
Active
Explore comprehensive insights into Linq Therapeutics Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Pathik Pradeep Divate | Director | 29 Sep 2015 | Current |
| Uma Pradeep Divate | Director | 29 Sep 2015 | Current |
| Cowasji Jehangir Jehangir | Director | 25 Nov 2020 | Current |
| Jehangir Hirji Cawasji Jehangir | Director | 29 Sep 2015 | Current |
| Geeta Pathik Divate | Director | 25 Nov 2020 | Current |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Linq Therapeutics Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 17.28% increase. The company also saw a substantial fall in profitability, with a 19.03% decrease in profit. The company's net worth Soared by an impressive increase of 99.18%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2019, Linq Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Linq Therapeutics has a workforce of 5 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Linq Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Linq Therapeutics's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Linq Therapeutics Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was documented.
Progress on Linq Therapeutics Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Pune. was documented.
Cowasji Jehangir Jehangir was appointed as a Director was appointed as a Director on 25 Nov 2020 & has been associated with this company since 5 years 1 month . was recorded as a recent event.
The activity Geeta Pathik Divate was appointed as a Director was appointed as a Director on 25 Nov 2020 & has been associated with this company since 5 years 1 month . was completed.
Pathik Pradeep Divate was appointed as a Director was appointed as a Director on 29 Sep 2015 & has been associated with this company since 10 years 3 months . was recorded as a recent event.
Progress on Uma Pradeep Divate was appointed as a Director was appointed as a Director on 29 Sep 2015 & has been associated with this company since 10 years 3 months . was documented.
The CIN of Linq Therapeutics Private Limited is U74999PN2015PTC156595.
Linq Therapeutics Private Limited is headquartered at Office No. 309-311, Millenium Star,, P 17 Fp 153 Cts 36 To 40, Sangamwadi, Pune City, Maharashtra, 411001.
Linq Therapeutics Private Limited was incorporated on 29 September 2015.
The current directors of Linq Therapeutics Private Limited are
The primary industry of Linq Therapeutics Private Limited is Healthcare.
Linq Therapeutics Private Limited is unlisted.
The authorized capital of Linq Therapeutics Private Limited is ₹5.00 M, and the paid-up capital is ₹5.00 M.
The compliance status of Linq Therapeutics Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX